EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates

Xiaodi Guo iD, Jie Xiang, Keqiang Ye, Zhentao Zhang iD

Cells · 2025

DOI: 10.3390/cells14120907 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Xiaodi Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: alpha-Synuclein, Positron-Emission Tomography, Protein Aggregates, Radiopharmaceuticals. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases (NDDs) that are characterized by the accumulation of alpha-synuclein (α-syn) aggregates in both neurons and the non-neuronal cells of the brain are called synucleinopathies. The most common synucleinopathies includes Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Significant progress has been made in the development of positron emission tomography (PET) radiotracers for synucleinopathies, yielding several α-syn tracers that have entered clinical studies. However, selective α-syn imaging still faces inherent challenges. This review provides a comprehensive overview of the progress in α-syn PET radiotracers from three angles: Alzheimer’s disease (AD)-derived scaffolds, representative compound scaffolds and analogs, and the identification of α-syn tracers through high-throughput screening (HTS). We discuss the characteristics, advantages, and limitations of the tracers for preclinical and clinical application. Finally, future directions in the development of radioligands for proteinopathies are discussed. There is no clinical available PET radiotracer for imaging α-syn aggregates, but these advances have laid a key foundation for non-invasive α-syn imaging and early diagnosis of synucleinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinPositron-Emission TomographyProtein AggregatesRadiopharmaceuticalsHumansAnimalsSynucleinopathies

Stichwörter der Autor:innen

Parkinson’s diseasehigh-throughput screeningsynucleinopathytracer

Substanzen

alpha-SynucleinProtein AggregatesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Department of Neurobiology, Fourth Military Medical University, Xi'an 710032, China.
  • Faculty of Life and Health Sciences, Shenzhen University of Advanced Technology (SUAT), Shenzhen 518055, China.
  • TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430000, China.

ORCID-Profile: Xiaodi Guo, Zhentao Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, X., Xiang, J., Ye, K., & Zhang, Z. (2025). Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates. Cells. https://doi.org/10.3390/cells14120907

Vancouver

Guo X, Xiang J, Ye K, Zhang Z. Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates. Cells. 2025. doi:10.3390/cells14120907

BibTeX
@article{Guo2025,
  author = {Guo, Xiaodi and Xiang, Jie and Ye, Keqiang and Zhang, Zhentao},
  title = {Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14120907}
}
Kostenlos starten →